Figure 4.

Polystructures of JC3 reveal an enhanced inhibitory effect of IFN-γ-induced IP-10/CXCL10 expression in orbital fibroblasts from patients with TAO patients. (a, b) Orbital fibroblasts from patients with TAO were treated with IFN-γ (10 ng ml⁻¹) in the presence of incremental doses of JC3 dimer (JC3-D, 0.1–10 μM) or JC3 trimer (JC3-T, 0.1–10 μM) as described in Figure 3. At the end of incubation, the supernatant was collected and analyzed by ELISA. (c) Cells were pretreated with 10 μM of JC3, JC3-D, or JC3-T, and the IP-10/CXCL10 level was assessed by ELISA. The IP-10/CXCL10 expression level of the IFN-γ-treated group was arbitrarily assigned a value of 100, and data are presented as percentage reductions (*P<0.05 vs IFN-γ-treated group; BD, below detection limit).